-
A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.
Pediatr DiabetesSosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, Diabetes Prevention Trial-Type 1 and TrialNet Study Groups. -
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes.
DiabetesGreenbaum CJ, Atkinson MA -
Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
PLoS OneLachin JM, McGee PL, Greenbaum CJ, Palmer JP, Pescovitz MD, Gottlieb PA, Skyler JS, Type 1 Diabetes Trial Network -
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).
DiabetesSosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer JP, Diabetes Prevention Trial-Type 1 Study Group. -
Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes.
Clin ImmunolSanda S, Bollyky J, Standifer N, Nepom GT, Hamerman JA, Greenbaum CJ -
National Institutes of Health Center for Human Immunology Conference, September 2009.
Ann N Y Acad SciNussenblatt RB, Bielekova B, Childs R, Krensky A, Strober W, Trinchieri G, Center for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Greenbaum CJ -
Omental roll-up: a technique for islet engraftment in a large animal model.
J Surg ResHefty TR, Kuhr CS, Chong KT, Guinee DG, Wang W, Reems JA, Greenbaum CJ -
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.
Diabetes CareGottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet MMF/DZB Study Group. -
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Diabetes CareSosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth G, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group. -
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
DiabetesLong SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum CJ, Buckner JH -
Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium.
Clin TrialsHall MA, King NM, Perdue LH, Hilner JE, Akolkar B, Greenbaum CJ, McKeon C, T1DGC. -
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
N Engl J MedPescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. -
Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study.
J PediatrPetitti DB, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder B, Mayer-Davis E, SEARCH for Diabetes in Youth Study Group., Greenbaum CJ -
Preservation of beta-cell function in autoantibody-positive youth with diabetes.
Diabetes CareGreenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G, Marcovina S, Pihoker C, SEARCH Study Group. -
Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.
Diabetes CareSosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group.
